产超广谱β-内酰胺酶肺炎克雷伯菌体外药效模型比较美罗培南单用及联合黏菌素的抗生物膜效果
Comparative Antibiofilm Efficacy of Meropenem Alone and in Combination with Colistin in an Pharmacodynamic Model by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae.
机构信息
Infectious Diseases Service, Laboratory of Experimental Infection, IDIBELL-Hospital Universitari de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Spain.
Department of Microbiology, IDIBELL-Hospital Universitari de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Spain.
出版信息
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01230-19. Print 2019 Nov.
Abstract
We compared the efficacies of meropenem alone and in combination with colistin against two strains of extended-spectrum-β-lactamase-producing , using an pharmacodynamic model that mimicked two different biofilm conditions. Meropenem monotherapy achieved remarkable efficacy (even a bactericidal effect) under all conditions, whereas colistin was almost inactive and resistance emerged. The addition of colistin to meropenem produced no relevant benefits, in contrast to experiences with other microorganisms.
摘要
我们比较了单独使用美罗培南和联合使用黏菌素治疗两种产超广谱β-内酰胺酶菌株的疗效，采用了一种药效动力学模型来模拟两种不同的生物膜条件。美罗培南单药治疗在所有条件下均显示出显著疗效（甚至杀菌作用），而黏菌素几乎无效且出现耐药性。与其他微生物的经验相反，黏菌素联合美罗培南治疗并没有带来相关益处。
相似文献
1
Comparative Antibiofilm Efficacy of Meropenem Alone and in Combination with Colistin in an Pharmacodynamic Model by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01230-19. Print 2019 Nov.
2
Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1925-1931. doi: 10.1007/s10096-019-03628-6. Epub 2019 Jul 6.
3
Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates.
J Antimicrob Chemother. 2019 Feb 1;74(2):387-394. doi: 10.1093/jac/dky422.
4
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
Antimicrob Agents Chemother. 2014;58(3):1757-62. doi: 10.1128/AAC.00741-13. Epub 2014 Jan 6.
5
In vitro synergy and postantibiotic effect of colistin combinations with meropenem and vancomycin against Enterobacteriaceae with multiple carbapenem resistance mechanisms.
J Infect Chemother. 2018 Dec;24(12):1016-1019. doi: 10.1016/j.jiac.2018.06.001. Epub 2018 Jul 11.
6
In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
Diagn Microbiol Infect Dis. 2013 Jul;76(3):335-8. doi: 10.1016/j.diagmicrobio.2013.04.004. Epub 2013 May 29.
7
Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Int J Antimicrob Agents. 2011 Mar;37(3):244-7. doi: 10.1016/j.ijantimicag.2010.10.031. Epub 2011 Jan 13.
8
Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniae.
J Antibiot (Tokyo). 2017 Aug;70(9):974-978. doi: 10.1038/ja.2017.73. Epub 2017 Jul 5.
9
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
J Antimicrob Chemother. 2017 Jul 1;72(7):1981-1984. doi: 10.1093/jac/dkx084.
10
Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments.
J Antimicrob Chemother. 2016 Aug;71(8):2321-5. doi: 10.1093/jac/dkw213. Epub 2016 Jun 21.
引用本文的文献
1
Structural Insights Into Papain-Derived Synthetic Antibacterial Peptides for Targeting Klebsiella pneumoniae.
Chem Biol Drug Des. 2025 May;105(5):e70130. doi: 10.1111/cbdd.70130.
2
Efficacy and safety of colistin plus beta-lactams for bone and joint infection caused by fluoroquinolone-resistant gram-negative bacilli: a prospective multicenter study.
Infection. 2025 Feb;53(1):359-372. doi: 10.1007/s15010-024-02379-7. Epub 2024 Sep 9.
3
Relationship between biofilm formation and antibiotic resistance of and updates on antibiofilm therapeutic strategies.
Front Cell Infect Microbiol. 2024 Feb 23;14:1324895. doi: 10.3389/fcimb.2024.1324895. eCollection 2024.
4
Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant .
Front Microbiol. 2022 Sep 23;13:1013934. doi: 10.3389/fmicb.2022.1013934. eCollection 2022.
本文引用的文献
1
Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Int J Antimicrob Agents. 2019 May;53(5):612-619. doi: 10.1016/j.ijantimicag.2019.01.010. Epub 2019 Jan 23.
2
Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant Klebsiella pneumoniae Biofilms.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02357-18. Print 2019 Mar.
3
Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.01018-18. Print 2018 Aug.
4
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.
5
Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm.
Int J Antimicrob Agents. 2018 Jun;51(6):854-861. doi: 10.1016/j.ijantimicag.2018.01.014. Epub 2018 Jan 31.
6
Investigation of the effects of various antibiotics against Klebsiella pneumoniae biofilms on in vitro catheter model.
J Chemother. 2018 Apr;30(2):82-88. doi: 10.1080/1120009X.2017.1390633. Epub 2017 Oct 24.
7
Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.
J Antimicrob Chemother. 2017 Dec 1;72(12):3357-3365. doi: 10.1093/jac/dkx288.
8
Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments.
J Antimicrob Chemother. 2016 Aug;71(8):2321-5. doi: 10.1093/jac/dkw213. Epub 2016 Jun 21.
9
Antibiofilm Peptides: Potential as Broad-Spectrum Agents.
J Bacteriol. 2016 Sep 9;198(19):2572-8. doi: 10.1128/JB.00017-16. Print 2016 Oct 1.
10
Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.
Infect Dis Ther. 2015 Dec;4(4):391-415. doi: 10.1007/s40121-015-0093-7. Epub 2015 Dec 8.
Zotero 插件